Free Trial
→ Musk’s Project Colossus could mint millionaires (From Brownstone Research) (Ad) Buy IMCR Stock  Free IMCR Stock Alerts

Immunocore (IMCR) Financials

Immunocore logo
$32.39 +1.39 (+4.48%)
Closing price 05/20/2025 04:00 PM Eastern
Extended Trading
$32.68 +0.29 (+0.90%)
As of 08:41 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Immunocore

Annual Income Statements for Immunocore

This table shows Immunocore's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018
Net Income / (Loss) Attributable to Common Shareholders		 -51 -55 -53 -180 -101 -138 -91
Consolidated Net Income / (Loss)		 -51 -55 -53 -180 -101 -138 -91
Net Income / (Loss) Continuing Operations		 -51 -55 -53 -180 -101 -138 -91
Total Pre-Tax Income 		-53 -61 -41 -180 -119 -167 -112
Total Operating Income		 -70 -60 -52 -175 -119 -157 -119
Total Gross Profit		 307 248 173 36 45 34 30
Total Revenue		 310 249 174 36 50 34 30
Operating Revenue		 310 249 174 36 50 34 30
Total Cost of Revenue		 2.73 1.04 1.09 0.00 4.61 0.00 0.00
Operating Cost of Revenue		 2.73 1.04 1.09 0.00 4.61 - -
Total Operating Expenses		 378 308 225 211 165 191 150
Selling, General & Admin Expense		 156 144 123 111 62 59 44
Research & Development Expense		 222 164 102 100 102 132 106
Total Other Income / (Expense), net		 18 -1.24 11 -5.29 0.00 -10 7.10
Interest Expense		 19 5.15 5.41 5.57 - 12 -5.65
Interest & Investment Income		 26 18 3.76 0.07 - 2.00 1.45
Other Income / (Expense), net		 11 -14 12 0.22 - - -
Income Tax Expense		 -1.85 -5.60 12 0.15 -18 -29 -21
Basic Earnings per Share		 ($1.02) ($1.13) ($1.15) ($4.24) ($2.79) ($4.66) ($3.32)
Weighted Average Basic Shares Outstanding		 49.99M 48.89M 45.71M 42.49M 31.78M - -
Diluted Earnings per Share		 ($1.02) ($1.13) ($1.15) ($4.24) ($2.79) ($4.66) ($3.32)
Weighted Average Diluted Shares Outstanding		 49.99M 48.89M 45.71M 42.49M 31.78M - -
Weighted Average Basic & Diluted Shares Outstanding		 50.07M 49.82M 48.09M 43.86M 31.78M - -
Cash Dividends to Common per Share		 $0.00 $0.00 $0.00 - - - -

Quarterly Income Statements for Immunocore

This table shows Immunocore's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Net Income / (Loss) Attributable to Common Shareholders		 5.02 -24 8.74 -12 -24 -20 0.91 -17 -19
Consolidated Net Income / (Loss)		 5.02 -24 8.74 -12 -24 -20 0.91 -17 -19
Net Income / (Loss) Continuing Operations		 5.02 -24 8.74 -12 -24 -20 0.91 -17 -19
Total Pre-Tax Income 		6.08 -25 6.09 -10 -24 -26 0.73 -17 -19
Total Operating Income		 -3.62 -19 -8.50 -16 -26 -17 -14 -14 -15
Total Gross Profit		 93 84 80 74 70 70 65 59 54
Total Revenue		 94 84 80 75 71 70 65 60 55
Operating Revenue		 94 84 80 75 71 70 65 60 55
Total Cost of Revenue		 0.83 0.33 0.45 1.71 0.25 0.20 0.28 0.35 0.22
Operating Cost of Revenue		 0.83 0.33 0.45 1.71 0.25 0.20 0.28 0.35 0.22
Total Operating Expenses		 97 103 88 90 97 87 79 73 69
Selling, General & Admin Expense		 40 42 36 39 39 41 35 35 33
Research & Development Expense		 56 61 53 51 57 46 43 38 37
Total Other Income / (Expense), net		 9.70 -5.37 15 5.89 2.41 -8.59 15 -3.07 -4.46
Interest Expense		 3.03 7.04 4.29 4.28 3.24 1.31 1.32 1.27 1.25
Interest & Investment Income		 4.18 5.17 5.96 6.24 8.25 5.44 5.14 4.28 3.13
Other Income / (Expense), net		 8.55 -3.50 13 3.93 -2.60 -13 11 -6.07 -6.34
Income Tax Expense		 1.06 -1.05 -2.64 1.49 0.36 -5.91 -0.18 0.19 0.29
Basic Earnings per Share		 $0.10 ($0.47) $0.17 ($0.23) ($0.49) ($0.40) $0.02 ($0.35) ($0.40)
Weighted Average Basic Shares Outstanding		 50.09M 49.99M 50.02M 50.01M 49.88M 48.89M 49.13M 48.69M 48.18M
Diluted Earnings per Share		 $0.10 ($0.47) $0.17 ($0.23) ($0.49) ($0.40) $0.02 ($0.35) ($0.40)
Weighted Average Diluted Shares Outstanding		 51.95M 49.99M 52.81M 50.01M 49.88M 48.89M 54.16M 48.69M 48.18M
Weighted Average Basic & Diluted Shares Outstanding		 50.23M 50.07M 50.03M 50.02M 50.01M 49.82M - - -

Annual Cash Flow Statements for Immunocore

This table details how cash moves in and out of Immunocore's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018
Net Change in Cash & Equivalents		 15 32 94 144 -181 -67 53
Net Cash From Operating Activities		 26 2.94 -49 -143 -126 -136 -21
Net Cash From Continuing Operating Activities		 26 2.94 -49 -143 -126 -172 -14
Net Income / (Loss) Continuing Operations		 -51 -55 -53 -180 -101 -138 -91
Consolidated Net Income / (Loss)		 -51 -55 -53 -180 -101 -138 -91
Depreciation Expense		 4.20 4.09 5.34 7.59 12 12 8.17
Non-Cash Adjustments To Reconcile Net Income		 28 48 22 49 -3.91 -15 62
Changes in Operating Assets and Liabilities, net		 45 5.78 -24 -22 -34 -31 5.87
Net Cash From Investing Activities		 -355 -5.43 -2.20 -1.28 0.00 -3.46 74
Net Cash From Continuing Investing Activities		 -355 -5.43 -2.20 -1.28 0.00 -3.46 74
Purchase of Property, Plant & Equipment		 -5.17 -5.43 -2.20 -1.39 - -5.67 -4.44
Purchase of Investments		 -350 0.00 0.00 - - - -0.06
Sale of Property, Plant & Equipment		 0.04 0.00 0.01 0.11 - 0.11 0.00
Net Cash From Financing Activities		 344 34 145 288 -55 73 0.13
Net Cash From Continuing Financing Activities		 344 34 145 288 -55 73 0.13
Repayment of Debt		 -65 0.00 -54 0.00 - -5.35 0.00
Other Financing Activities, net		 409 34 199 288 -55 0.04 0.13
Cash Interest Received		 -9.24 5.67 -4.48 - - - -
Cash Income Taxes Paid		 0.51 0.98 0.77 17 - - -

Quarterly Cash Flow Statements for Immunocore

This table details how cash moves in and out of Immunocore's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Net Change in Cash & Equivalents		 13 -69 20 -328 391 -12 20 10 14
Net Cash From Operating Activities		 0.44 -14 21 23 -4.59 -18 10 0.05 11
Net Cash From Continuing Operating Activities		 0.44 -14 21 23 -4.59 -18 10 0.05 11
Net Income / (Loss) Continuing Operations		 5.02 -24 8.74 -12 -24 -20 0.91 -17 -19
Consolidated Net Income / (Loss)		 5.02 -24 8.74 -12 -24 -20 0.91 -17 -19
Depreciation Expense		 0.85 1.17 1.04 0.99 1.01 1.03 1.08 1.03 0.95
Non-Cash Adjustments To Reconcile Net Income		 2.17 17 -6.66 6.87 11 22 -2.66 13 16
Changes in Operating Assets and Liabilities, net		 -7.61 -8.25 18 27 8.14 -21 11 2.57 13
Net Cash From Investing Activities		 9.70 -3.54 -0.83 -350 -0.43 -0.82 -0.21 -1.40 -3.00
Net Cash From Continuing Investing Activities		 9.70 -3.54 -0.83 -350 -0.43 -0.82 -0.21 -1.40 -3.00
Purchase of Property, Plant & Equipment		 -0.30 -3.58 -0.83 -0.33 -0.43 -0.82 -0.21 -1.40 -3.00
Sale and/or Maturity of Investments		 10 - - - - - - - -
Net Cash From Financing Activities		 2.55 -52 0.20 -0.82 396 6.25 10 12 6.14
Net Cash From Continuing Financing Activities		 2.55 -52 0.20 -0.82 396 6.25 10 12 6.14
Repayment of Debt		 0.00 -52 - -1.12 -12 - - - 0.00
Issuance of Debt		 0.00 - - - - - - - -
Other Financing Activities, net		 2.55 0.55 0.20 0.30 408 6.25 10 12 6.14
Cash Interest Received		 -5.03 -17 -4.83 6.98 5.14 -0.03 1.25 2.87 1.58
Cash Income Taxes Paid		 0.03 0.16 0.29 0.20 -0.14 0.76 - 0.44 -0.22

Annual Balance Sheets for Immunocore

This table presents Immunocore's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Total Assets		 1,010 597 527 407 269 246
Total Current Assets		 930 529 474 355 209 165
Cash & Equivalents		 456 443 402 321 177 98
Short-Term Investments		 365 0.00 - - 0.00 0.35
Accounts Receivable		 63 52 34 21 14 13
Inventories, net		 5.45 4.50 0.69 0.00 - -
Prepaid Expenses		 41 30 37 - - -
Plant, Property, & Equipment, net		 10 9.22 7.83 12 19 24
Total Noncurrent Assets		 70 59 45 41 42 57
Noncurrent Deferred & Refundable Income Taxes		 15 11 5.12 3.48 3.05 2.00
Other Noncurrent Operating Assets		 55 48 40 37 39 55
Total Liabilities & Shareholders' Equity		 1,010 597 527 407 269 246
Total Liabilities		 649 228 188 176 194 226
Total Current Liabilities		 212 139 101 83 75 112
Accounts Payable		 25 18 14 48 35 39
Accrued Expenses		 186 120 77 - - 38
Other Current Liabilities		 1.55 1.39 1.88 35 40 9.62
Total Noncurrent Liabilities		 437 89 87 93 119 114
Long-Term Debt		 391 48 48 50 50 0.00
Noncurrent Deferred Revenue		 5.43 5.52 5.24 - - 64
Other Noncurrent Operating Liabilities		 40 36 34 8.73 34 0.14
Commitments & Contingencies		 0.00 0.00 - - - -
Total Equity & Noncontrolling Interests		 361 369 339 232 76 20
Total Preferred & Common Equity		 361 369 339 232 76 20
Total Common Equity		 361 369 339 -55 76 -356
Common Stock		 1,190 1,150 1,083 0.12 0.09 0.00
Retained Earnings		 -796 -745 -689 -650 -478 -370
Accumulated Other Comprehensive Income / (Loss)		 -34 -36 -55 - - -
Other Equity Adjustments		 0.00 0.00 0.00 595 553 14

Quarterly Balance Sheets for Immunocore

This table presents Immunocore's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024
Period end date 3/31/2025 9/30/2024 6/30/2024 3/31/2024
Total Assets		 1,028 1,085 1,023 994
Total Current Assets		 949 1,006 957 926
Cash & Equivalents		 477 538 505 833
Short-Term Investments		 360 364 355 -
Accounts Receivable		 63 64 60 58
Inventories, net		 6.80 4.52 3.46 4.17
Prepaid Expenses		 42 36 34 31
Plant, Property, & Equipment, net		 9.77 9.16 7.68 8.38
Total Noncurrent Assets		 70 70 59 60
Noncurrent Deferred & Refundable Income Taxes		 14 13 10 11
Other Noncurrent Operating Assets		 55 57 49 49
Total Liabilities & Shareholders' Equity		 1,028 1,085 1,023 994
Total Liabilities		 650 707 664 634
Total Current Liabilities		 149 266 185 155
Accounts Payable		 29 20 20 16
Accrued Expenses		 118 197 164 139
Other Current Liabilities		 1.72 1.10 1.39 1.24
Total Noncurrent Liabilities		 500 441 479 479
Long-Term Debt		 392 390 438 438
Noncurrent Deferred Revenue		 5.61 5.80 5.48 5.47
Other Noncurrent Operating Liabilities		 103 44 36 36
Commitments & Contingencies		 0.00 - - -
Total Equity & Noncontrolling Interests		 378 378 359 360
Total Preferred & Common Equity		 378 378 359 360
Total Common Equity		 378 378 359 360
Common Stock		 1,202 1,181 1,174 1,164
Retained Earnings		 -791 -772 -781 -769
Accumulated Other Comprehensive Income / (Loss)		 -33 -31 -34 -35
Other Equity Adjustments		 0.00 0.00 0.00 0.00

Annual Metrics And Ratios for Immunocore

This table displays calculated financial ratios and metrics derived from Immunocore's official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018
Growth Metrics		 - - - - - - -
Revenue Growth		 24.37% 43.05% 377.91% -26.94% 46.81% 12.87% 0.00%
EBITDA Growth		 20.29% -105.43% 79.42% -53.86% 25.96% -30.82% 0.00%
EBIT Growth		 19.01% -87.92% 77.50% -46.15% 23.90% -31.68% 0.00%
NOPAT Growth		 -18.13% -15.36% 70.38% -46.33% 23.90% -31.68% 0.00%
Net Income Growth		 7.60% -5.22% 70.81% -77.91% 26.52% -50.91% 0.00%
EPS Growth		 9.73% 1.74% 72.88% -51.97% 40.13% -40.36% 0.00%
Operating Cash Flow Growth		 786.43% 105.97% 65.61% -13.26% 7.33% -543.74% 0.00%
Free Cash Flow Firm Growth		 79.69% -24.45% 81.00% -94.37% 35.51% 0.00% 0.00%
Invested Capital Growth		 -166.36% -63.51% -210.69% 70.34% -543.89% 0.00% 0.00%
Revenue Q/Q Growth		 4.69% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 11.13% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 10.24% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 -3.53% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 -8.59% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 -7.37% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 16.98% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 19.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - -
Gross Margin		 99.12% 99.58% 99.38% 100.00% 90.77% 100.00% 100.00%
EBITDA Margin		 -17.89% -27.92% -19.44% -451.44% -214.37% -425.05% -366.74%
Operating Margin		 -22.71% -23.91% -29.66% -478.53% -238.92% -460.95% -395.09%
EBIT Margin		 -19.25% -29.56% -22.50% -477.94% -238.92% -460.95% -395.09%
Profit (Net Income) Margin		 -16.47% -22.17% -30.13% -493.45% -202.64% -404.89% -302.82%
Tax Burden Percent		 96.51% 90.80% 128.52% 100.08% 84.81% 82.36% 81.23%
Interest Burden Percent		 88.66% 82.59% 104.21% 103.16% 100.00% 106.65% 94.35%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -14.00% -15.62% -18.42% -117.22% -212.67% -703.62% 0.00%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -7.43% -13.12% -8.40% -51.54% -46.31% -63.73% 0.00%
Return on Assets (ROA)		 -6.36% -9.84% -11.25% -53.21% -39.27% -55.98% 0.00%
Return on Common Equity (ROCE)		 -14.00% -15.62% -9.17% -7.88% 626.16% 12,788.97% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 -14.16% -14.99% -15.50% -77.74% -133.87% -703.62% 0.00%
Net Operating Profit after Tax (NOPAT)		 -49 -42 -36 -122 -84 -110 -83
NOPAT Margin		 -15.90% -16.74% -20.76% -334.97% -167.25% -322.66% -276.56%
Net Nonoperating Expense Percent (NNEP)		 -0.43% -3.61% -5.53% -35.11% -30.76% -251.63% 0.00%
Return On Investment Capital (ROIC_SIMPLE)		 -6.56% -10.02% -9.36% - - - -
Cost of Revenue to Revenue		 0.88% 0.42% 0.62% 0.00% 9.23% 0.00% 0.00%
SG&A Expenses to Revenue		 50.22% 57.93% 70.58% 303.76% 125.10% 172.13% 144.40%
R&D to Revenue		 71.61% 65.57% 58.45% 274.77% 204.60% 389.54% 353.32%
Operating Expenses to Revenue		 121.83% 123.50% 129.03% 578.53% 329.69% 561.67% 497.42%
Earnings before Interest and Taxes (EBIT)		 -60 -74 -39 -174 -119 -157 -119
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -56 -70 -34 -165 -107 -145 -111
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 4.09 8.91 7.39 0.00 3.42 0.00 0.00
Price to Tangible Book Value (P/TBV)		 4.09 8.91 7.39 0.00 3.42 0.00 0.00
Price to Revenue (P/Rev)		 4.76 13.17 14.36 29.83 5.17 7.60 8.57
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 3.37 11.59 12.32 31.19 3.32 17.98 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 40.16 983.26 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - -
Debt to Equity		 1.08 0.13 0.14 0.36 1.12 3.89 0.00
Long-Term Debt to Equity		 1.08 0.13 0.14 0.36 1.12 2.59 0.00
Financial Leverage		 -1.13 -1.06 -1.04 -1.07 -1.21 -1.14 0.00
Leverage Ratio		 2.20 1.59 1.64 2.20 5.42 12.57 0.00
Compound Leverage Factor		 1.95 1.31 1.71 2.27 5.42 13.40 0.00
Debt to Total Capital		 52.02% 11.52% 12.36% 26.73% 52.77% 79.55% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 26.52% 0.00%
Long-Term Debt to Total Capital		 52.02% 11.52% 12.36% 26.73% 52.77% 53.03% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 90.65% 0.00% 392.17% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 47.98% 88.48% 87.64% -17.38% 47.23% -371.72% 0.00%
Debt to EBITDA		 -7.04 -0.69 -1.41 -0.51 -0.79 -0.53 0.00
Net Debt to EBITDA		 7.74 5.67 10.46 1.44 0.87 0.15 0.00
Long-Term Debt to EBITDA		 -7.04 -0.69 -1.41 -0.51 -0.79 -0.35 0.00
Debt to NOPAT		 -7.93 -1.15 -1.32 -0.69 -1.01 -0.69 0.00
Net Debt to NOPAT		 8.71 9.45 9.80 1.94 1.11 0.20 0.00
Long-Term Debt to NOPAT		 -7.93 -1.15 -1.32 -0.69 -1.01 -0.46 0.00
Altman Z-Score		 1.23 7.69 7.10 0.96 -2.36 -3.13 0.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 50.22% 93.28% 394.42% 1,917.61% 0.00%
Liquidity Ratios		 - - - - - - -
Current Ratio		 4.38 3.80 4.70 4.29 2.78 1.47 0.00
Quick Ratio		 4.16 3.56 4.32 4.14 2.55 0.99 0.00
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 -6.45 -32 -26 -134 -69 -107 0.00
Operating Cash Flow to CapEx		 508.11% 54.19% -2,239.83% -11,180.16% 0.00% -2,453.53% -476.94%
Free Cash Flow to Firm to Interest Expense		 -0.34 -6.16 -4.72 -24.09 0.00 -8.62 0.00
Operating Cash Flow to Interest Expense		 1.38 0.57 -9.10 -25.68 0.00 -10.97 0.00
Operating Cash Flow Less CapEx to Interest Expense		 1.11 -0.48 -9.50 -25.91 0.00 -11.42 0.00
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.39 0.44 0.37 0.11 0.19 0.14 0.00
Accounts Receivable Turnover		 5.39 5.82 6.44 2.11 3.72 2.66 0.00
Inventory Turnover		 0.55 0.40 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 32.13 29.26 17.52 2.36 2.32 1.40 0.00
Accounts Payable Turnover		 0.13 0.06 0.04 0.00 0.12 0.00 0.00
Days Sales Outstanding (DSO)		 67.72 62.69 56.64 172.93 97.99 137.06 0.00
Days Inventory Outstanding (DIO)		 664.71 913.91 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 2,866.67 5,675.27 10,438.63 0.00 2,939.00 0.00 0.00
Cash Conversion Cycle (CCC)		 -2,134.24 -4,698.68 -10,381.99 172.93 -2,841.01 137.06 0.00
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 -69 -26 -16 -5.07 -17 -2.66 0.00
Invested Capital Turnover		 -6.57 -12.01 -16.74 -3.29 -5.05 -25.61 0.00
Increase / (Decrease) in Invested Capital		 -43 -10 -11 12 -14 -2.66 0.00
Enterprise Value (EV)		 1,047 2,891 2,149 1,138 166 611 0.00
Market Capitalization		 1,476 3,285 2,503 1,088 258 258 258
Book Value per Share		 $7.21 $7.67 $7.73 ($1.73) $2.38 ($35.81) $0.00
Tangible Book Value per Share		 $7.21 $7.67 $7.73 ($1.73) $2.38 ($35.81) $0.00
Total Capital		 752 417 387 316 160 96 0.00
Total Debt		 391 48 48 84 84 76 0.00
Total Long-Term Debt		 391 48 48 84 84 51 0.00
Net Debt		 -429 -395 -355 -237 -93 -22 0.00
Capital Expenditures (CapEx)		 5.13 5.43 2.20 1.28 0.00 5.56 4.44
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -103 -53 -29 -49 -43 -20 0.00
Debt-free Net Working Capital (DFNWC)		 718 390 373 272 134 78 0.00
Net Working Capital (NWC)		 718 390 373 272 134 53 0.00
Net Nonoperating Expense (NNE)		 1.76 14 16 58 18 28 7.91
Net Nonoperating Obligations (NNO)		 -429 -395 -355 -237 -93 -22 0.00
Total Depreciation and Amortization (D&A)		 4.20 4.09 5.34 9.67 12 12 8.54
Debt-free, Cash-free Net Working Capital to Revenue		 -33.11% -21.18% -16.82% -134.47% -86.92% -59.63% 0.00%
Debt-free Net Working Capital to Revenue		 231.36% 156.28% 214.01% 745.77% 267.84% 229.56% 0.00%
Net Working Capital to Revenue		 231.36% 156.28% 214.01% 745.77% 267.84% 154.93% 0.00%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 ($1.02) ($1.13) ($0.90) ($3.10) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 49.99M 48.89M 48.09M 43.86M 31.78M 0.00 0.00
Adjusted Diluted Earnings per Share		 ($1.02) ($1.13) ($0.90) ($3.10) $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 49.99M 48.89M 48.09M 43.86M 31.78M 0.00 0.00
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 50.07M 49.82M 48.09M 43.86M 31.78M 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -49 -42 -36 -122 -84 -110 -83
Normalized NOPAT Margin		 -15.90% -16.74% -20.76% -334.97% -167.25% -322.66% -276.56%
Pre Tax Income Margin		 -17.07% -24.41% -23.45% -493.04% -238.92% -491.60% -372.78%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 -3.17 -14.30 -7.25 -31.29 0.00 -12.62 0.00
NOPAT to Interest Expense		 -2.62 -8.10 -6.69 -21.93 0.00 -8.83 0.00
EBIT Less CapEx to Interest Expense		 -3.44 -15.36 -7.66 -31.52 0.00 -13.06 0.00
NOPAT Less CapEx to Interest Expense		 -2.89 -9.15 -7.10 -22.16 0.00 -9.28 0.00
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% -0.71% 0.00%

Quarterly Metrics And Ratios for Immunocore

This table displays calculated financial ratios and metrics derived from Immunocore's official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Growth Metrics		 - - - - - - - - -
Revenue Growth		 33.16% 19.80% 23.74% 26.18% 28.99% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 120.93% 24.18% 371.14% 40.95% -39.80% 0.00% 0.00% 0.00% 0.00%
EBIT Growth		 116.96% 22.89% 243.14% 39.01% -38.28% 0.00% 0.00% 0.00% 0.00%
NOPAT Growth		 83.90% -14.07% 30.46% -16.43% -80.25% 0.00% 0.00% 0.00% 0.00%
Net Income Growth		 120.56% -20.48% 864.24% 31.73% -25.64% 0.00% 0.00% 0.00% 0.00%
EPS Growth		 120.41% -17.50% 750.00% 34.29% -22.50% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Growth		 109.48% 21.33% 109.41% 52,060.00% -143.52% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Growth		 64.49% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Growth		 -87.51% -166.36% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Revenue Q/Q Growth		 11.69% 4.74% 6.43% 6.95% 0.00% 8.19% 8.52% 9.33% 0.00%
EBITDA Q/Q Growth		 126.56% -499.23% 149.17% 60.46% 0.00% -1,327.67% 89.29% 6.39% 0.00%
EBIT Q/Q Growth		 121.49% -619.01% 136.58% 58.43% 0.00% -863.46% 84.42% 5.74% 0.00%
NOPAT Q/Q Growth		 78.08% -11.70% -8.72% 39.54% 0.00% 31.91% -82.04% 6.39% 0.00%
Net Income Q/Q Growth		 121.13% -372.10% 175.21% 52.46% 0.00% -2,277.70% 105.33% 12.52% 0.00%
EPS Q/Q Growth		 121.28% -376.47% 173.91% 53.06% 0.00% -2,100.00% 105.71% 12.50% 0.00%
Operating Cash Flow Q/Q Growth		 103.12% -166.03% -9.99% 611.71% 0.00% -275.77% 22,320.00% -99.57% 0.00%
Free Cash Flow Firm Q/Q Growth		 -3.30% -59.68% 41.94% 197.25% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 2.37% 19.01% -35.97% -74.41% 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - - - -
Gross Margin		 99.11% 99.61% 99.44% 97.74% 99.65% 99.72% 99.57% 99.42% 99.60%
EBITDA Margin		 6.16% -25.92% 6.80% -14.72% -39.82% -40.96% -3.10% -31.46% -36.74%
Operating Margin		 -3.85% -23.14% -10.59% -21.24% -37.57% -24.30% -21.81% -23.02% -26.89%
EBIT Margin		 5.25% -27.31% 5.51% -16.04% -41.26% -42.43% -4.76% -33.18% -38.48%
Profit (Net Income) Margin		 5.35% -28.28% 10.89% -15.41% -34.66% -28.12% 1.40% -28.47% -35.58%
Tax Burden Percent		 82.56% 95.77% 143.38% 114.67% 101.48% 76.94% 123.94% 101.14% 101.53%
Interest Burden Percent		 123.33% 108.12% 137.76% 83.77% 82.79% 86.13% -23.66% 84.85% 91.07%
Effective Tax Rate		 17.44% 0.00% -43.38% 0.00% 0.00% 0.00% -23.94% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -5.86% -14.00% -12.45% -15.28% -16.76% -15.62% 0.00% 0.00% 0.00%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 1.73% -10.55% 1.51% -4.40% -11.01% -18.84% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 1.77% -10.92% 2.97% -4.23% -9.25% -12.48% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -5.86% -14.00% -12.45% -15.28% -16.76% -15.62% 0.00% 0.00% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 -5.71% 0.00% -12.45% -15.28% -16.76% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -2.99 -14 -12 -11 -19 -12 -18 -9.63 -10
NOPAT Margin		 -3.18% -16.20% -15.19% -14.87% -26.30% -17.01% -27.03% -16.12% -18.82%
Net Nonoperating Expense Percent (NNEP)		 1.91% -2.46% 9.05% -0.19% -2.98% -1.98% 0.00% 0.00% 0.00%
Return On Investment Capital (ROIC_SIMPLE)		 -0.39% -1.81% - - - -2.86% - - -
Cost of Revenue to Revenue		 0.89% 0.39% 0.56% 2.26% 0.35% 0.28% 0.43% 0.58% 0.40%
SG&A Expenses to Revenue		 42.82% 50.35% 44.28% 51.24% 55.72% 59.08% 54.69% 58.59% 59.58%
R&D to Revenue		 60.15% 72.40% 65.76% 67.73% 81.50% 64.94% 66.69% 63.86% 66.91%
Operating Expenses to Revenue		 102.97% 122.75% 110.04% 118.98% 137.22% 124.02% 121.38% 122.44% 126.49%
Earnings before Interest and Taxes (EBIT)		 4.93 -23 4.42 -12 -29 -30 -3.09 -20 -21
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 5.79 -22 5.46 -11 -28 -29 -2.01 -19 -20
Valuation Ratios		 - - - - - - - - -
Price to Book Value (P/BV)		 3.93 4.09 4.12 4.72 8.69 8.91 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 3.93 4.09 4.12 4.72 8.69 8.91 0.00 0.00 0.00
Price to Revenue (P/Rev)		 4.45 4.76 5.25 6.03 11.78 13.17 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 3.12 3.37 3.69 4.53 10.29 11.59 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 33.46 40.16 49.13 113.28 0.00 983.26 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - -
Debt to Equity		 1.03 1.08 1.16 1.22 1.22 0.13 0.00 0.00 0.00
Long-Term Debt to Equity		 1.03 1.08 1.03 1.22 1.22 0.13 0.00 0.00 0.00
Financial Leverage		 -1.14 -1.13 -1.22 -1.17 -1.10 -1.07 0.00 0.00 0.00
Leverage Ratio		 2.74 2.20 2.87 2.85 2.76 1.59 0.00 0.00 0.00
Compound Leverage Factor		 3.38 2.38 3.95 2.39 2.29 1.37 0.00 0.00 0.00
Debt to Total Capital		 50.85% 52.02% 53.73% 54.95% 54.89% 11.52% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 5.90% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 50.85% 52.02% 47.82% 54.95% 54.89% 11.52% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 49.15% 47.98% 46.27% 45.05% 45.11% 88.48% 0.00% 0.00% 0.00%
Debt to EBITDA		 -18.09 -7.04 -7.02 -6.27 -5.64 -0.69 0.00 0.00 0.00
Net Debt to EBITDA		 20.58 7.74 7.41 6.03 5.09 5.67 0.00 0.00 0.00
Long-Term Debt to EBITDA		 -18.09 -7.04 -6.25 -6.27 -5.64 -0.69 0.00 0.00 0.00
Debt to NOPAT		 -11.75 -7.93 -9.21 -8.49 -8.75 -1.15 0.00 0.00 0.00
Net Debt to NOPAT		 13.37 8.71 9.71 8.17 7.90 9.45 0.00 0.00 0.00
Long-Term Debt to NOPAT		 -11.75 -7.93 -8.20 -8.49 -8.75 -1.15 0.00 0.00 0.00
Altman Z-Score		 1.57 1.35 1.43 1.60 2.97 7.93 0.00 0.00 0.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - -
Current Ratio		 6.36 4.38 3.78 5.17 5.96 3.80 0.00 0.00 0.00
Quick Ratio		 6.03 4.16 3.62 4.97 5.73 3.56 0.00 0.00 0.00
Cash Flow Metrics		 - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 28 29 73 51 17 0.00 0.00 0.00 0.00
Operating Cash Flow to CapEx		 145.97% -389.26% 2,551.57% 7,091.24% -1,066.74% -2,170.50% 4,758.96% 3.23% 351.18%
Free Cash Flow to Firm to Interest Expense		 9.35 4.16 16.92 11.95 5.31 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.14 -1.98 4.92 5.49 -1.42 -13.55 7.64 0.04 8.43
Operating Cash Flow Less CapEx to Interest Expense		 0.05 -2.49 4.73 5.41 -1.55 -14.17 7.48 -1.06 6.03
Efficiency Ratios		 - - - - - - - - -
Asset Turnover		 0.33 0.39 0.27 0.27 0.27 0.44 0.00 0.00 0.00
Accounts Receivable Turnover		 5.52 5.39 4.65 4.66 4.59 5.82 0.00 0.00 0.00
Inventory Turnover		 0.60 0.55 0.58 0.70 0.26 0.40 0.00 0.00 0.00
Fixed Asset Turnover		 36.76 32.13 32.35 36.56 31.66 29.26 0.00 0.00 0.00
Accounts Payable Turnover		 0.15 0.13 0.13 0.12 0.07 0.06 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 66.12 67.72 78.42 78.28 79.47 62.69 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 603.80 664.71 634.26 520.44 1,425.45 913.91 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 2,454.94 2,866.67 2,768.53 2,998.62 5,302.59 5,675.27 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 -1,785.03 -2,134.24 -2,055.85 -2,399.90 -3,797.67 -4,698.68 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - -
Invested Capital		 -67 -69 -85 -62 -36 -26 0.00 0.00 0.00
Invested Capital Turnover		 -6.49 -6.57 -6.99 -9.01 -14.84 -9.68 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -31 -43 -85 -62 -36 0.00 0.00 0.00 0.00
Enterprise Value (EV)		 1,040 1,047 1,094 1,273 2,730 2,891 0.00 0.00 0.00
Market Capitalization		 1,486 1,476 1,557 1,695 3,126 3,285 2,496 2,883 2,377
Book Value per Share		 $7.56 $7.21 $7.55 $7.18 $7.21 $7.67 $0.00 $0.00 $0.00
Tangible Book Value per Share		 $7.56 $7.21 $7.55 $7.18 $7.21 $7.67 $0.00 $0.00 $0.00
Total Capital		 770 752 817 797 797 417 0.00 0.00 0.00
Total Debt		 392 391 439 438 438 48 0.00 0.00 0.00
Total Long-Term Debt		 392 391 390 438 438 48 0.00 0.00 0.00
Net Debt		 -446 -429 -463 -421 -395 -395 0.00 0.00 0.00
Capital Expenditures (CapEx)		 0.30 3.58 0.83 0.33 0.43 0.82 0.21 1.40 3.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -38 -103 -113 -88 -62 -53 0.00 0.00 0.00
Debt-free Net Working Capital (DFNWC)		 799 718 788 772 771 390 0.00 0.00 0.00
Net Working Capital (NWC)		 799 718 740 772 771 390 0.00 0.00 0.00
Net Nonoperating Expense (NNE)		 -8.01 10 -21 0.40 5.89 7.79 -18 7.38 9.16
Net Nonoperating Obligations (NNO)		 -446 -429 -463 -421 -395 -395 0.00 0.00 0.00
Total Depreciation and Amortization (D&A)		 0.85 1.17 1.04 0.99 1.01 1.03 1.08 1.03 0.95
Debt-free, Cash-free Net Working Capital to Revenue		 -11.26% -33.11% -38.28% -31.27% -23.40% -21.18% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 239.66% 231.36% 265.89% 274.73% 290.55% 156.28% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 239.66% 231.36% 249.62% 274.73% 290.55% 156.28% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.10 ($0.47) $0.17 ($0.23) ($0.49) ($0.40) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 50.09M 49.99M 50.02M 50.01M 49.88M 48.89M 0.00 0.00 0.00
Adjusted Diluted Earnings per Share		 $0.10 ($0.47) $0.17 ($0.23) ($0.49) ($0.40) $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 51.95M 49.99M 52.81M 50.01M 49.88M 48.89M 0.00 0.00 0.00
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 50.23M 50.07M 50.03M 50.02M 50.01M 49.82M 0.00 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -2.99 -14 -5.95 -11 -19 -12 -9.90 -9.63 -10
Normalized NOPAT Margin		 -3.18% -16.20% -7.42% -14.87% -26.30% -17.01% -15.27% -16.12% -18.82%
Pre Tax Income Margin		 6.48% -29.53% 7.59% -13.44% -34.15% -36.55% 1.13% -28.15% -35.05%
Debt Service Ratios		 - - - - - - - - -
EBIT to Interest Expense		 1.63 -3.26 1.03 -2.83 -8.98 -22.74 -2.34 -15.56 -16.83
NOPAT to Interest Expense		 -0.99 -1.93 -2.84 -2.62 -5.72 -9.12 -13.27 -7.56 -8.23
EBIT Less CapEx to Interest Expense		 1.53 -3.77 0.84 -2.90 -9.11 -23.37 -2.50 -16.66 -19.23
NOPAT Less CapEx to Interest Expense		 -1.09 -2.44 -3.03 -2.70 -5.86 -9.74 -13.43 -8.65 -10.63
Payout Ratios		 - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Immunocore's Financials

When does Immunocore's fiscal year end?

According to the most recent income statement we have on file, Immunocore's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Immunocore's net income changed over the last 6 years?

Immunocore's net income appears to be on a downward trend, with a most recent value of -$51.09 million in 2024, falling from -$91.26 million in 2018. The previous period was -$55.29 million in 2023. See Immunocore's forecast for analyst expectations on what’s next for the company.

What is Immunocore's operating income?
Immunocore's total operating income in 2024 was -$70.46 million, based on the following breakdown:
  • Total Gross Profit: $307.47 million
  • Total Operating Expenses: $377.93 million
How has Immunocore revenue changed over the last 6 years?

Over the last 6 years, Immunocore's total revenue changed from $30.13 million in 2018 to $310.20 million in 2024, a change of 929.4%.

How much debt does Immunocore have?

Immunocore's total liabilities were at $648.79 million at the end of 2024, a 184.4% increase from 2023, and a 186.5% increase since 2019.

How much cash does Immunocore have?

In the past 5 years, Immunocore's cash and equivalents has ranged from $98.01 million in 2019 to $455.73 million in 2024, and is currently $455.73 million as of their latest financial filing in 2024.

How has Immunocore's book value per share changed over the last 6 years?

Over the last 6 years, Immunocore's book value per share changed from 0.00 in 2018 to 7.21 in 2024, a change of 721.0%.


Related Companies

This page (NASDAQ:IMCR) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsored
Gold Hits New Highs as Global Markets Spiral
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...
Premier Gold Co | Sponsored
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
Paradigm Press | Sponsored
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...
Porter & Company | Sponsored
Silicon Valley Gold Rush
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...
Stansberry Research | Sponsored
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...
Golden Portfolio | Sponsored
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...
Timothy Sykes | Sponsored